PARENTERAL ALANYL-GLUTAMMINE IN CRITICALLY ILL PATIENTS- A BAYESIAN META-ANALYSIS OF PUBLISHED TRIALS
Author(s)
Pradelli L1, Zaniolo O1, Iannazzo S1, Eandi M21Adres SRL, Torino, Italy, 2University of Torino, Torino, Italy
Presentation Documents
OBJECTIVES: Glutamine, although abundant in human tissue, can become conditionally essential in clinical conditions with hyper-catabolism and glutathione depletion (burns, pancreatic necrosis, surgical complications), but has not been added to parenteral nutrition solutions for a long time, for its alleged non-essentiality and the low solubility and stability in aqueous solutions, which have been solved by conjugation with alanine. In 2002 a meta-analysis of available trials conducted with alanylglutamine dipeptide revealed significant reductions of mortality, infections and ICU length of stay. Since then, data from other trials have become available. Aim of the present study is to update the treatment effect estimates by means of a series of Bayesian random effects models. METHODS: We searched EMBASE and Medline for clinical trials of standard total parenteral nutrition (TPN) vs. TPN + parenteral alanylglutamine in critically ill patients reporting hospital mortality, relative ICU-incident infection rate, and relative hospital length of stay. For each outcome, a series of Bayesian random effects models was specified, in which the treatment effect observed in the individual trials is assumed to be drawn from a common distribution and expressed as a relative risk or duration. RESULTS: Outcomes from 15 trials and 781 patients were retrieved. The main models, i.e. simple hierarchy random effects models with neutral priors, estimate a relative mortality of 0.70 (95% CrI: 0.46-0.97), a relative infection rate of 0.71 (95% CrI: 0.49-0.97), and a relative length of stay of 0.91 (95% CrI: 0.76-1.00). Secondary analyses indicated some heterogeneity in the magnitude and reliability of the benefits in sub-groups of the wider critically ill patient population. The incorporation of prior knowledge leads to significantly more precise estimates and permits to obtain comfortable reliability even on subgroup-specific treatment effects estimates. CONCLUSIONS: In conclusion, the available evidence supports a highly credible beneficial effect of alanylglutamine on mortality, infections and hospital length of stay in ICU-admitted critically ill patients.
Conference/Value in Health Info
2010-11, ISPOR Europe 2010, Prague, Czech Republic
Value in Health, Vol. 13, No. 7 (November 2010)
Code
PIH3
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Pediatrics, Reproductive and Sexual Health